Specialty Business Services
Compare Stocks
5 / 10Stock Comparison
TIC vs ULS vs TISI vs EMR vs HON
Revenue, margins, valuation, and 5-year total return — side by side.
Specialty Business Services
Specialty Business Services
Industrial - Machinery
Conglomerates
TIC vs ULS vs TISI vs EMR vs HON — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Specialty Business Services | Specialty Business Services | Specialty Business Services | Industrial - Machinery | Conglomerates |
| Market Cap | $2.21B | $19.96B | $78M | $79.02B | $136.91B |
| Revenue (TTM) | $1.78B | $3.11B | $885M | $18.32B | $36.76B |
| Net Income (TTM) | $-103M | $349M | $-53M | $2.44B | $4.10B |
| Gross Margin | 31.8% | 49.6% | 26.1% | 52.7% | 36.9% |
| Operating Margin | -0.6% | 17.8% | 1.1% | 19.8% | 14.9% |
| Forward P/E | 70.4x | 45.5x | — | 21.7x | 20.5x |
| Total Debt | $1.71B | $832M | $369M | $13.76B | $34.58B |
| Cash & Equiv. | $440M | $295M | $36M | $1.54B | $12.49B |
TIC vs ULS vs TISI vs EMR vs HON — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| TIC Solutions, Inc. (TIC) | 100 | 81.0 | -19.0% |
| UL Solutions Inc. (ULS) | 100 | 186.8 | +86.8% |
| Team, Inc. (TISI) | 100 | 105.6 | +5.6% |
| Emerson Electric Co. (EMR) | 100 | 116.0 | +16.0% |
| Honeywell Internati… (HON) | 100 | 101.5 | +1.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TIC vs ULS vs TISI vs EMR vs HON
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TIC ranks third and is worth considering specifically for growth.
- 39.4% revenue growth vs TISI's -1.2%
ULS has the current edge in this matchup, primarily because of its strength in sleep-well-at-night.
- Lower volatility, beta 0.73, Low D/E 64.3%, current ratio 1.32x
- +42.7% vs TISI's -19.0%
- 11.9% ROA vs TISI's -9.9%, ROIC 23.1% vs 2.2%
TISI is the clearest fit if your priority is stability.
- Beta 0.47 vs TIC's 1.65
EMR is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 3.0%, EPS growth 17.8%, 3Y rev CAGR 9.3%
- 206.6% 10Y total return vs ULS's 187.3%
- PEG 4.81 vs HON's 11.18
- Lower P/E (21.7x vs 45.5x), PEG 4.81 vs 6.85
HON is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 15 yrs, beta 0.74, yield 2.1%
- Beta 0.74, yield 2.1%, current ratio 1.32x
- 2.1% yield, 15-year raise streak, vs EMR's 1.5%, (2 stocks pay no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 39.4% revenue growth vs TISI's -1.2% | |
| Value | Lower P/E (21.7x vs 45.5x), PEG 4.81 vs 6.85 | |
| Quality / Margins | 13.3% margin vs TISI's -5.9% | |
| Stability / Safety | Beta 0.47 vs TIC's 1.65 | |
| Dividends | 2.1% yield, 15-year raise streak, vs EMR's 1.5%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +42.7% vs TISI's -19.0% | |
| Efficiency (ROA) | 11.9% ROA vs TISI's -9.9%, ROIC 23.1% vs 2.2% |
TIC vs ULS vs TISI vs EMR vs HON — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
TIC vs ULS vs TISI vs EMR vs HON — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ULS leads in 2 of 6 categories
EMR leads 1 • TISI leads 1 • TIC leads 0 • HON leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
EMR leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HON is the larger business by revenue, generating $36.8B annually — 41.5x TISI's $885M. EMR is the more profitable business, keeping 13.3% of every revenue dollar as net income compared to TISI's -5.9%. On growth, TIC holds the edge at +108.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.8B | $3.1B | $885M | $18.3B | $36.8B |
| EBITDAEarnings before interest/tax | $197M | $742M | $44M | $4.7B | $6.5B |
| Net IncomeAfter-tax profit | -$103M | $349M | -$53M | $2.4B | $4.1B |
| Free Cash FlowCash after capex | -$945,100 | $300M | -$16M | $3.1B | $4.2B |
| Gross MarginGross profit ÷ Revenue | +31.8% | +49.6% | +26.1% | +52.7% | +36.9% |
| Operating MarginEBIT ÷ Revenue | -0.6% | +17.8% | +1.1% | +19.8% | +14.9% |
| Net MarginNet income ÷ Revenue | -5.8% | +11.2% | -5.9% | +13.3% | +11.2% |
| FCF MarginFCF ÷ Revenue | -0.1% | +9.7% | -1.8% | +17.0% | +11.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +108.4% | +7.5% | +6.7% | +2.9% | -6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.5% | +36.4% | -6.3% | +28.2% | -41.9% |
Valuation Metrics
TISI leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 29.4x trailing earnings, HON trades at a 53% valuation discount to ULS's 62.1x P/E. Adjusting for growth (PEG ratio), EMR offers better value at 7.73x vs HON's 15.99x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.2B | $20.0B | $78M | $79.0B | $136.9B |
| Enterprise ValueMkt cap + debt − cash | $3.5B | $20.5B | $411M | $91.2B | $159.0B |
| Trailing P/EPrice ÷ TTM EPS | -16.97x | 62.09x | -2.00x | 34.92x | 29.36x |
| Forward P/EPrice ÷ next-FY EPS est. | 70.44x | 45.49x | — | 21.71x | 20.52x |
| PEG RatioP/E ÷ EPS growth rate | — | 9.35x | — | 7.73x | 15.99x |
| EV / EBITDAEnterprise value multiple | 18.66x | 27.04x | 8.85x | 18.07x | 19.99x |
| Price / SalesMarket cap ÷ Revenue | 1.45x | 6.54x | 0.09x | 4.39x | 3.66x |
| Price / BookPrice ÷ Book value/share | 0.72x | 15.58x | 44.06x | 3.94x | 9.00x |
| Price / FCFMarket cap ÷ FCF | 36.12x | 49.53x | 5.85x | 29.63x | 25.39x |
Profitability & Efficiency
ULS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ULS delivers a 28.1% return on equity — every $100 of shareholder capital generates $28 in annual profit, vs $-164 for TISI. ULS carries lower financial leverage with a 0.64x debt-to-equity ratio, signaling a more conservative balance sheet compared to TISI's 212.04x. On the Piotroski fundamental quality scale (0–9), ULS scores 7/9 vs TIC's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.5% | +28.1% | -164.5% | +12.1% | +23.1% |
| ROA (TTM)Return on assets | -2.7% | +11.9% | -9.9% | +5.8% | +5.3% |
| ROICReturn on invested capital | +0.2% | +23.1% | +2.2% | +8.2% | +12.6% |
| ROCEReturn on capital employed | +0.3% | +24.8% | +2.7% | +10.0% | +12.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 5 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.79x | 0.64x | 212.04x | 0.68x | 2.24x |
| Net DebtTotal debt minus cash | $1.3B | $537M | $333M | $12.2B | $22.1B |
| Cash & Equiv.Liquid assets | $440M | $295M | $36M | $1.5B | $12.5B |
| Total DebtShort + long-term debt | $1.7B | $832M | $369M | $13.8B | $34.6B |
| Interest CoverageEBIT ÷ Interest expense | 0.01x | 25.46x | 0.21x | 6.46x | 3.92x |
Total Returns (Dividends Reinvested)
ULS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ULS five years ago would be worth $28,729 today (with dividends reinvested), compared to $1,943 for TISI. Over the past 12 months, ULS leads with a +42.7% total return vs TISI's -19.0%. The 3-year compound annual growth rate (CAGR) favors TISI at 54.7% vs TIC's -5.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.2% | +23.0% | +21.5% | +4.3% | +10.9% |
| 1-Year ReturnPast 12 months | -1.5% | +42.7% | -19.0% | +30.4% | +2.8% |
| 3-Year ReturnCumulative with dividends | -16.6% | +187.3% | +270.2% | +75.9% | +16.2% |
| 5-Year ReturnCumulative with dividends | -16.6% | +187.3% | -80.6% | +59.5% | +3.3% |
| 10-Year ReturnCumulative with dividends | -16.6% | +187.3% | -93.7% | +206.6% | +135.1% |
| CAGR (3Y)Annualised 3-year return | -5.9% | +42.2% | +54.7% | +20.7% | +5.1% |
Risk & Volatility
Evenly matched — ULS and TISI each lead in 1 of 2 comparable metrics.
Risk & Volatility
TISI is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than TIC's 1.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ULS currently trades 92.4% from its 52-week high vs TIC's 67.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.65x | 0.73x | 0.47x | 1.52x | 0.74x |
| 52-Week HighHighest price in past year | $14.94 | $107.54 | $24.25 | $165.15 | $248.18 |
| 52-Week LowLowest price in past year | $6.36 | $61.64 | $12.34 | $108.37 | $186.76 |
| % of 52W HighCurrent price vs 52-week peak | +67.0% | +92.4% | +71.3% | +85.4% | +87.1% |
| RSI (14)Momentum oscillator 0–100 | 76.6 | 76.5 | 55.9 | 61.3 | 45.1 |
| Avg Volume (50D)Average daily shares traded | 3.1M | 704K | 6K | 2.8M | 3.7M |
Analyst Outlook
Evenly matched — EMR and HON each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: TIC as "Hold", ULS as "Buy", EMR as "Buy", HON as "Buy". Consensus price targets imply 49.9% upside for TIC (target: $15) vs -10.0% for ULS (target: $89). For income investors, HON offers the higher dividend yield at 2.14% vs ULS's 0.52%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | $89.40 | — | $161.92 | $243.83 |
| # AnalystsCovering analysts | 2 | 8 | — | 41 | 28 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | — | +1.5% | +2.1% |
| Dividend StreakConsecutive years of raises | 1 | 1 | 0 | 37 | 15 |
| Dividend / ShareAnnual DPS | — | $0.51 | — | $2.10 | $4.63 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +1.6% | +2.8% |
ULS leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). EMR leads in 1 (Income & Cash Flow). 2 tied.
TIC vs ULS vs TISI vs EMR vs HON: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TIC or ULS or TISI or EMR or HON a better buy right now?
For growth investors, TIC Solutions, Inc.
(TIC) is the stronger pick with 39. 4% revenue growth year-over-year, versus -1. 2% for Team, Inc. (TISI). Honeywell International Inc. (HON) offers the better valuation at 29. 4x trailing P/E (20. 5x forward), making it the more compelling value choice. Analysts rate UL Solutions Inc. (ULS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TIC or ULS or TISI or EMR or HON?
On trailing P/E, Honeywell International Inc.
(HON) is the cheapest at 29. 4x versus UL Solutions Inc. at 62. 1x. On forward P/E, Honeywell International Inc. is actually cheaper at 20. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Emerson Electric Co. wins at 4. 81x versus Honeywell International Inc. 's 11. 18x.
03Which is the better long-term investment — TIC or ULS or TISI or EMR or HON?
Over the past 5 years, UL Solutions Inc.
(ULS) delivered a total return of +187. 3%, compared to -80. 6% for Team, Inc. (TISI). Over 10 years, the gap is even starker: EMR returned +206. 6% versus TISI's -93. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TIC or ULS or TISI or EMR or HON?
By beta (market sensitivity over 5 years), Team, Inc.
(TISI) is the lower-risk stock at 0. 47β versus TIC Solutions, Inc. 's 1. 65β — meaning TIC is approximately 251% more volatile than TISI relative to the S&P 500. On balance sheet safety, UL Solutions Inc. (ULS) carries a lower debt/equity ratio of 64% versus 212% for Team, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — TIC or ULS or TISI or EMR or HON?
By revenue growth (latest reported year), TIC Solutions, Inc.
(TIC) is pulling ahead at 39. 4% versus -1. 2% for Team, Inc. (TISI). On earnings-per-share growth, the picture is similar: Team, Inc. grew EPS 50. 1% year-over-year, compared to -353. 8% for TIC Solutions, Inc.. Over a 3-year CAGR, EMR leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TIC or ULS or TISI or EMR or HON?
Emerson Electric Co.
(EMR) is the more profitable company, earning 12. 7% net margin versus -5. 7% for TIC Solutions, Inc. — meaning it keeps 12. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMR leads at 19. 6% versus 0. 6% for TIC. At the gross margin level — before operating expenses — EMR leads at 52. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TIC or ULS or TISI or EMR or HON more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Emerson Electric Co. (EMR) is the more undervalued stock at a PEG of 4. 81x versus Honeywell International Inc. 's 11. 18x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Honeywell International Inc. (HON) trades at 20. 5x forward P/E versus 70. 4x for TIC Solutions, Inc. — 49. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TIC: 49. 9% to $15. 00.
08Which pays a better dividend — TIC or ULS or TISI or EMR or HON?
In this comparison, HON (2.
1% yield), EMR (1. 5% yield), ULS (0. 5% yield) pay a dividend. TIC, TISI do not pay a meaningful dividend and should not be held primarily for income.
09Is TIC or ULS or TISI or EMR or HON better for a retirement portfolio?
For long-horizon retirement investors, UL Solutions Inc.
(ULS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73), 0. 5% yield, +187. 3% 10Y return). TIC Solutions, Inc. (TIC) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ULS: +187. 3%, TIC: -16. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TIC and ULS and TISI and EMR and HON?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TIC is a small-cap high-growth stock; ULS is a mid-cap quality compounder stock; TISI is a small-cap quality compounder stock; EMR is a mid-cap quality compounder stock; HON is a mid-cap quality compounder stock. ULS, EMR, HON pay a dividend while TIC, TISI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.